Boston Scientific exercises an option it acquired in 2004 as part of a corporate venturing deal to buy heart treatment company Cameron Health for up to $1.35bn.
New York-listed Boston Scientific has acquired a company it previously backed in a corporate venturing deal, buying heart treatment company Cameron Health for up to $1.35bn.
The acquisition is for an upfront sum of $150m, followed by $150m upon FDA approval of the company’s main product, plus up $1.05bn if the company makes revenue-based milestones during the six-year period following FDA approval. Cameron Health is not the only Boston Scientific portfolio company it has acquired in the last two years.…
